Boston Scientific Co. (BSX) Shares Bought by Toronto Dominion Bank

Toronto Dominion Bank grew its position in Boston Scientific Co. (NYSE:BSX) by 20.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,013,085 shares of the medical equipment provider’s stock after acquiring an additional 169,323 shares during the quarter. Toronto Dominion Bank’s holdings in Boston Scientific were worth $38,872,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. We Are One Seven LLC purchased a new position in Boston Scientific in the fourth quarter worth $27,000. Ipswich Investment Management Co. Inc. purchased a new position in shares of Boston Scientific in the 4th quarter worth about $28,000. Athena Capital Advisors LLC purchased a new position in shares of Boston Scientific in the 4th quarter worth about $28,000. Essex Savings Bank purchased a new position in shares of Boston Scientific in the 1st quarter worth about $31,000. Finally, CWM LLC raised its holdings in shares of Boston Scientific by 54.3% in the 4th quarter. CWM LLC now owns 1,020 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 359 shares during the period. 91.61% of the stock is owned by institutional investors and hedge funds.

In related news, EVP David A. Pierce sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $37.10, for a total transaction of $185,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Maulik Nanavaty sold 3,039 shares of the business’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $40.32, for a total value of $122,532.48. The disclosure for this sale can be found here. Insiders have sold a total of 298,116 shares of company stock valued at $11,926,744 in the last 90 days. Insiders own 0.66% of the company’s stock.

BSX has been the topic of a number of research reports. Needham & Company LLC restated a “buy” rating and issued a $43.00 price objective on shares of Boston Scientific in a report on Wednesday, February 6th. Guggenheim restated a “buy” rating and issued a $48.00 price objective on shares of Boston Scientific in a report on Friday, February 8th. SunTrust Banks restated a “buy” rating and issued a $47.00 price objective on shares of Boston Scientific in a report on Friday, February 8th. Canaccord Genuity restated a “buy” rating and issued a $45.00 price objective on shares of Boston Scientific in a report on Monday, February 11th. Finally, Argus raised their price objective on Boston Scientific from $43.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, February 13th. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $41.53.

Shares of BSX traded up $0.82 during mid-day trading on Tuesday, hitting $36.79. The stock had a trading volume of 134,412 shares, compared to its average volume of 7,828,117. The firm has a market cap of $50.87 billion, a price-to-earnings ratio of 24.97, a PEG ratio of 2.19 and a beta of 0.83. The company has a current ratio of 1.39, a quick ratio of 1.12 and a debt-to-equity ratio of 0.82. Boston Scientific Co. has a fifty-two week low of $29.42 and a fifty-two week high of $41.00.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 24th. The medical equipment provider reported $0.35 EPS for the quarter, missing the consensus estimate of $0.36 by ($0.01). Boston Scientific had a return on equity of 24.65% and a net margin of 18.08%. The firm had revenue of $2.49 billion during the quarter, compared to analyst estimates of $2.54 billion. During the same quarter in the previous year, the business posted $0.33 EPS. Boston Scientific’s revenue was up 4.8% compared to the same quarter last year. On average, sell-side analysts predict that Boston Scientific Co. will post 1.55 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Boston Scientific Co. (BSX) Shares Bought by Toronto Dominion Bank” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2019/05/14/boston-scientific-co-bsx-shares-bought-by-toronto-dominion-bank.html.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Read More: Coverage Ratio

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.